Education and Qualifications:
- Second Faculty of Medicine, Charles University in Prague, 2005
- Fellow of the European Board of Urology (FEBU), 2010
- Specialist qualification in Urology, 2011
- Postgraduate studies in Experimental Surgery, Second Faculty of Medicine, Charles University in Prague, 2019
- Defense of doctoral thesis; awarded Ph.D. degree, 2019
- Specialist qualification in Oncourology, 2020
- Defense of habilitation thesis; awarded title of Associate Professor of Urology; appointment by the Rector of Charles University, 2023
- Assistant Professor, Department of Urology, Second Faculty of Medicine, Charles University in Prague, 2016–present
Internships and Professional Experience:
- Department of Urology, University Hospital Motol (FNM), Prague – Head of Outpatient Department; focus on urologic oncology, oncological and robotic surgery, and reconstructive urology (2005–present)
- Clinical Fellowship: Department of Urology, Skåne University Hospital, Malmö, Sweden (Head: Prof. Per-Anders Abrahamsson, M.D., Ph.D.), 2011
- General Surgery and Cardiac Surgery, Brescia, Italy (2003, 4 weeks)
- Hand Surgery and Plastic Surgery, Vysoké nad Jizerou, Czech Republic (2003, 2 weeks)
- 11/2006 Laparoscopy, Prague
- 4/2008 Urothelial Tumors, Prague
- 4/2009 Laparoscopy in Urology, Prague
- 4/2009 Pediatric Urology, Prague
- 5/2009 Reconstructive Urology and Traumatology, Prague
- 6/2009 Urologic Oncology I, Prague
- 11/2009 Urologic Oncology II, Prague
- 12/2009 Neurourology, LUTS, and BPH, Prague
- Participation in various specialized courses held during EAU, CEM, and ČUS congresses
- Specialization training for board certification in urologic oncology (2018–2020)
- Repeated robotic surgery courses in Ghent, Belgium (2017–2018)
Publications:
(first author only; journals with Impact Factor or significant publications without Impact Factor):
- Brisuda A, Horňák J, Žemličková B, Háček J, Babjuk M. Intravesical thermochemotherapy in the treatment of high-risk and very high-risk non-muscle-invasive urothelial bladder cancer: a single-arm study. Int Urol Nephrol. 2024 Jul;56(7):2243-2250.
- Brisuda A, Ho JCS, Kandiyal PS, et al. Bladder cancer therapy using a conformationally fluid tumoricidal peptide complex. Nat Commun. 2021;12(1):3427.
- Brisuda A, Pazourkova E, Soukup V, Horinek A, Hrbacek J, Capoun O, Svobodova I, Pospisilova S, Korabecna M, Mares J, Hanus T, Babjuk M. Urinary Cell-Free DNA Quantification as Non-Invasive Biomarker in Patients with Bladder Cancer. Urol Int. 2016;96(1):25-31. IF 1.611
- Brisuda A, Háček J, Čechová M, Škapa P, Babjuk M. Clinical and cytopathological factors affecting the cellularity of urinary cell blocks and the implication for diagnosis and follow-up of urinary bladder urothelial carcinoma. Cytopathology. 2018 Dec;29(6):537-544. IF 1.376
- Brisuda A, Háček J, Čechová M, Škapa P, Babjuk M. Diagnosis of urinary bladder urothelial carcinoma by immunocytology with p53, MCM5, MCM2 and Ki-67 antibodies using cell blocks derived from urine.Cytopathology. 2019 Sep;30(5):510-518. IF 1.376
- Brisuda A. How to predict the risk of complication or death after radical cystectomy?
- Cent European J Urol. 2015;68(3):277. Brisuda A, Hrbáček J, Babjuk M: Treatment of Low-risk Non-muscle-invasive Bladder Cancer. European Urological Review 7(1):24-28.
